B Risberg, DW Tsui, H Biggs, A Ruiz-Valdepenas Martin de Almagro, S-J Dawson, C Hodgkin, L Jones, C Parkinson, A Piskorz, F Marass, D Chandrananda, E Moore, J Morris, V Plagnol, N Rosenfeld, C Caldas, JD Brenton, D Gale
Journal name: 
J Mol Diagn
Circulating tumor DNA (ctDNA) offers new opportunities for non-invasive cancer management. Detecting ctDNA in plasma is challenging since it constitutes only a minor fraction of the total cell-free DNA (cfDNA). Pre-analytical factors affect cfDNA levels contributed from leukocyte lysis, hence the ability to detect low-frequency mutant alleles. This study investigates the effects of the i) delay in processing, ii) storage temperatures, iii) different blood collection tubes, iv) centrifugation protocols, and v) sample shipment on cfDNA levels. Peripheral blood (n=231) from cancer patients (n=62) were collected into K3EDTA or Cell-free DNA BCT® (BCT) tubes and analyzed by digital PCR, targeted amplicon, or shallow whole-genome (sWGS) sequencing. To assess pre-analytic effects, plasma was processed under different conditions after 0h, 6h, 24h, 48h, 96h, and 1 week at room temperature or 4 °C, or using different centrifugation protocols. Digital PCR showed that cfDNA levels increased gradually with time in K3EDTA tubes, but were stable in BCT tubes. K3EDTA samples stored at 4 °C showed less variation than room temperature storage, but levels were elevated compared to BCT. A second centrifugation at 3000g gave similar cfDNA yields compared to higher speed centrifugation. Next-generation sequencing showed negligible differences in background error or copy number changes between K3EDTA and BCT, or following shipment in BCT. This study provides insights into the effects of sample processing on ctDNA analysis.
Research group: 
Caldas Group, Brenton Group, Rosenfeld Group
E-pub date: 
31 Jul 2018
Users with this publication listed: 
Carlos Caldas
Davina Gale
Dineika Chandrananda
James Brenton
Nitzan Rosenfeld